Cargando…

Impact of the COVID-19 pandemic on adults with moderate-to-severe atopic dermatitis in the Dutch general population

Detalles Bibliográficos
Autores principales:	Zhang, Junfen, Loman, Laura, Kamphuis, Esmé, Schuttelaar, Marie L.A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712261/ https://www.ncbi.nlm.nih.gov/pubmed/34977818 http://dx.doi.org/10.1016/j.jdin.2021.12.006

Ejemplares similares

Association between moderate to severe atopic dermatitis and lifestyle factors in the Dutch general population
por: Zhang, Junfen, et al.
Publicado: (2022)

Beyond Anxiety and Depression: Loneliness and Psychiatric Disorders in Adults with Atopic Dermatitis
por: ZHANG, Junfen, et al.
Publicado: (2023)

Hand eczema and lifestyle factors in the Dutch general population: Evidence for smoking, chronic stress, and obesity
por: Loman, Laura, et al.
Publicado: (2021)

Prevalence and Severity of Hand Eczema in the Dutch General Population: A Cross-sectional, Questionnaire Study within the Lifelines Cohort Study
por: VOORBERG, Angelique N., et al.
Publicado: (2022)

Smoking and obesity are associated with chronic hand eczema and severity of hand eczema: Data from the Dutch general population
por: Loman, L., et al.
Publicado: (2022)

The long‐term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis—52 week results from the Dutch BioDay Registry
por: Voorberg, Angelique N., et al.
Publicado: (2022)

Therapeutic clothing use in atopic dermatitis in the Netherlands: A population based cohort study
por: Ragamin, Aviël, et al.
Publicado: (2023)

Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28‐week clinical and biomarker results from the BioDay registry
por: Kamphuis, Esmé, et al.
Publicado: (2022)

Dupilumab therapy following JAK inhibitor withdrawal in moderate–severe atopic dermatitis
por: Kiely, Lisa, et al.
Publicado: (2022)

Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry
por: BOESJES, Celeste M., et al.
Publicado: (2022)

Ocular surface disease is common in moderate‐to‐severe atopic dermatitis patients
por: Achten, Roselie E., et al.
Publicado: (2022)

Three cases of non‐atopic hyperkeratotic hand eczema treated with dupilumab
por: Loman, Laura, et al.
Publicado: (2020)

Successfully and safety use of dupilumab in the management of severe atopic dermatitis and concomitant moderate‐to‐severe hidradenitis suppurativa
por: Molinelli, Elisa, et al.
Publicado: (2022)

Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
por: Bernardo, Diana, et al.
Publicado: (2023)

The positive effect of dupilumab on comorbid asthma in patients with atopic dermatitis
por: Spekhorst, Lotte S., et al.
Publicado: (2023)

Outcomes of COVID-19 and Vaccination in Patients With Moderate to Severe Atopic Dermatitis Treated With Tralokinumab
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Population Pharmacokinetics of Tralokinumab in Adult Subjects With Moderate to Severe Atopic Dermatitis
por: Soehoel, Anders, et al.
Publicado: (2022)

Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Association of Moderate–Severe Atopic Dermatitis with Dental Anomalies
por: Tan, Sean Y., et al.
Publicado: (2022)

Perceived adherence and associated barriers to the national atopic dermatitis guideline: A survey among general practitioners
por: Ragamin, Aviël, et al.
Publicado: (2023)

Use of cyclosporine in children and adolescents with moderate to severe atopic dermatitis: clinical experience in a tertiary Hospital()
por: Proença, Carolina Contin, et al.
Publicado: (2023)

Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
por: Kuznik, Andreas, et al.
Publicado: (2017)

Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial
por: Paller, Amy S., et al.
Publicado: (2023)

Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis
por: Hulshof, Lies, et al.
Publicado: (2018)

Apremilast Use for Moderate-to-Severe Atopic Dermatitis in Pediatric Patients
por: Saporito, Rachael C., et al.
Publicado: (2016)

Correction to: Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis
por: Esposito, Maria, et al.
Publicado: (2022)

Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study
por: Oosterhaven, Jart A.F., et al.
Publicado: (2019)

Baricitinib treatment of severe chronic hand eczema: Two case reports
por: Rosenberg, Fieke M., et al.
Publicado: (2022)

Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry
por: ARIËNS, Lieneke F. M., et al.
Publicado: (2021)

Remote severity assessment in atopic dermatitis: Validity and reliability of the remote Eczema Area and Severity Index and Self-Administered Eczema Area and Severity Index
por: Ragamin, Aviël, et al.
Publicado: (2023)

Allergic contact dermatitis masquerading as atopic dermatitis
por: Semaan, Sarah, et al.
Publicado: (2020)

Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis
por: Eichenfield, Lawrence F., et al.
Publicado: (2020)

Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
por: Xu, Xinghua, et al.
Publicado: (2017)

Increased Risk of Renal Malignancy in Patients with Moderate to Severe Atopic Dermatitis
por: Oh, Jongwook, et al.
Publicado: (2023)

Quantifying Costs Associated with Atopic Dermatitis
por: Ellis, Charles N., et al.
Publicado: (2003)

Prevalence of atopic dermatitis in adults()
por: Angles, Maria Valeria, et al.
Publicado: (2022)

Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE
por: Gooderham, Melinda J., et al.
Publicado: (2021)

Association between yearlong air pollution and moderate-severe atopic dermatitis: A United States cross-sectional claims analysis
por: Trinh, Pavin, et al.
Publicado: (2023)

Clinical Approach to Patients with Moderate-to-Severe Atopic Dermatitis: A Spanish Delphi Consensus
por: PEREYRA-RODRIGUEZ, Jose J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vmmjnrc9r1nsqvgafk05ktanfk